Search - tctmd.com

Displaying 21 - 40 of 44

Sort: Relevancy | Date

News Daily News

Research Clarifies Link Between BP Problems in Pregnancy and Later CVD

Yael L. Maxwell

June 13, 2022

Presentation TVT 2022

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Presenter: Sanjiv Shah

June 10, 2022

RELIEVE HF: Different Patient Selection and Study Design – Should We Expect Different Results?

Presentation TVT 2022

Less Invasive Ventricular Enhancement for HFrEF

Presenter: John Boehmer

June 10, 2022

Presentation TVT 2022

What (Else) Have We Learned From REDUCE-LAP II?

Presenter: Sanjiv Shah

June 10, 2022

Presentation TVT 2022

Overview of the Interatrial Shunt Device Landscape: Conceptual Basis and Devices

Presenter: Daniel Burkhoff

June 10, 2022

Presentation TVT 2022

Transcatheter Closure of An Atypical Sinus Venosus Atrial Septal Defect with Mitigation of Pulmonary Vein Compression

Presenter: Nino Mihatov

June 10, 2022

Presentation TVT 2022

The Cardiovalve Trans-septal System: Device Design and Clinical Program Update

Presenter: D. Scott Lim

June 10, 2022

Presentation TVT 2022

The Cephea Trans-septal System: EFS Program Update

Presenter: Vinod H. Thourani

June 10, 2022

Presentation TVT 2022

The SafeCross Trans-septal Crossing System

Presenter: Lauren Sharan Ranard

June 10, 2022

Presentation TVT 2022

The Protaryx™ Trans-septal Crossing System

Presenter: James S. Gammie

June 10, 2022

Presentation TVT 2022

Planning the Trans-septal Puncture: Tailoring Location Based on LAAO Anatomy (With Case Examples)

Presenter: Devi Nair

June 09, 2022

Presentation TVT 2022

Characterization and management of iatrogenic atrial septal defects after transseptal transcatheter mitral valve replacement with the Sapien 3 valve

Presenter: Lauren Ranard

June 09, 2022

Presentation TVT 2022

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Presenter: David Hsi

June 09, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Advertisement

Research Clarifies Link Between BP Problems in Pregnancy and Later CVD

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Less Invasive Ventricular Enhancement for HFrEF

What (Else) Have We Learned From REDUCE-LAP II?

Overview of the Interatrial Shunt Device Landscape: Conceptual Basis and Devices

Transcatheter Closure of An Atypical Sinus Venosus Atrial Septal Defect with Mitigation of Pulmonary Vein Compression

The Cardiovalve Trans-septal System: Device Design and Clinical Program Update

The Cephea Trans-septal System: EFS Program Update

The SafeCross Trans-septal Crossing System

The Protaryx™ Trans-septal Crossing System

Planning the Trans-septal Puncture: Tailoring Location Based on LAAO Anatomy (With Case Examples)

Characterization and management of iatrogenic atrial septal defects after transseptal transcatheter mitral valve replacement with the Sapien 3 valve

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content